Carmen D. Zorrilla to Male
This is a "connection" page, showing publications Carmen D. Zorrilla has written about Male.
Connection Strength
0.353
-
Lebov JF, Arias JF, Balmaseda A, Britt W, Cordero JF, Galv?o LA, Garces AL, Hambidge KM, Harris E, Ko A, Krebs N, Marques ETA, Martinez AM, McClure E, Miranda-Filho DB, Moreira MEL, Mussi-Pinhata MM, Ochoa TJ, Osorio JE, Scalabrin DMF, Schultz-Cherry S, Seage GR, Stolka K, Ugarte-Gil CA, Vega CMV, Welton M, Ximenes R, Zorrilla C. International prospective observational cohort study of Zika in infants and pregnancy (ZIP study): study protocol. BMC Pregnancy Childbirth. 2019 Aug 07; 19(1):282.
Score: 0.048
-
Col?n-L?pez V, Ortiz AP, P?rez N, Acevedo E, Tamayo V, Zorrilla CD. Measuring Knowledge of Cancer Screening and Prevention Strategies in HIV Healthcare Professionals. P R Health Sci J. 2016 09; 35(3):147-53.
Score: 0.039
-
Silva-Su?rez G, Bastida E, Rabionet SE, Beck-Sagu? C, Febo I, Zorrilla CD. "That's True Love:" Lived Experiences of Puerto Rican Perinatally HIV-Infected Youth within Their Families' Context. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010007.
Score: 0.037
-
Jim?ez J, Morales M, Castro E, Puig M, V?lez CN, Santiago L, Zorrilla C. Levels of felt stigma among a group of people with HIV in Puerto Rico. P R Health Sci J. 2012 Jun; 31(2):64-70.
Score: 0.029
-
Jimenez JC, Puig M, Ramos JC, Morales M, Asencio G, Sala AC, Castro E, Velez Santori C, Santiago L, Zorrilla C. Measuring HIV felt stigma: a culturally adapted scale targeting PLWHA in Puerto Rico. AIDS Care. 2010 Nov; 22(11):1314-22.
Score: 0.026
-
Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015 Sep; 16(8):502-11.
Score: 0.018
-
Weinberg A, Muresan P, Fenton T, Richardson K, Dominguez T, Bloom A, Petzold E, Anthony P, Cunningham CK, Spector SA, Nachman S, Siberry GK, Handelsman E, Flynn PM. High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088). Hum Vaccin Immunother. 2013 May; 9(5):957-68.
Score: 0.015
-
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012 Jul 15; 206(2):258-66.
Score: 0.015
-
Valdes V, Zorrilla CD, Gabard-Durnam L, Muler-Mendez N, Rahman ZI, Rivera D, Nelson CA. Cognitive Development of Infants Exposed to the Zika Virus in Puerto Rico. JAMA Netw Open. 2019 10 02; 2(10):e1914061.
Score: 0.012
-
Liu AY, Norwood A, Gundacker H, Carballo-Di?guez A, Johnson S, Patterson K, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Mayer KH, Zorrilla C, Buchbinder S, Piper JM, Lama JR, Cranston RD. Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017). J Acquir Immune Defic Syndr. 2019 08 15; 81(5):516-520.
Score: 0.012
-
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008 Nov 29; 372(9653):1881-1893.
Score: 0.011
-
McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008 Nov 29; 372(9653):1894-1905.
Score: 0.011
-
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008 Oct 02; 359(14):1429-41.
Score: 0.011
-
F?tkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008 Oct 02; 359(14):1442-55.
Score: 0.011
-
Carballo-Di?guez A, Giguere R, Dolezal C, Leu CS, Bal?n IC, Brown W, Rael C, Richardson BA, Piper JM, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla CD, Lama JR, McGowan I, Cranston RD. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men. AIDS Behav. 2017 Dec; 21(12):3336-3345.
Score: 0.011
-
Carballo-Di?guez A, Bal?n IC, Brown W, Giguere R, Dolezal C, Leu CS, Marzinke MA, Hendrix CW, Piper JM, Richardson BA, Grossman C, Johnson S, Gomez K, Horn S, Kunjara Na Ayudhya RP, Patterson K, Jacobson C, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla C, Lama J, McGowan I, Cranston RD. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS One. 2017; 12(7):e0181607.
Score: 0.010
-
Cranston RD, Lama JR, Richardson BA, Carballo-Di?guez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu CS, Galaska B, Jacobson CE, Parikh UM, Marzinke MA, Hendrix CW, Johnson S, Piper JM, Grossman C, Ho KS, Lucas J, Pickett J, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu AY, Mayer KH, Zorrilla C, Schwartz JL, Rooney J, McGowan I. MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clin Infect Dis. 2017 03 01; 64(5):614-620.
Score: 0.010
-
Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16; 378(9787):229-37.
Score: 0.007
-
Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010 Sep 21; 153(6):349-57.
Score: 0.006
-
Djomand G, Metch B, Zorrilla CD, Donastorg Y, Casapia M, Villafana T, Pape J, Figueroa P, Hansen M, Buchbinder S, Beyrer C. The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2008 May 01; 48(1):82-9.
Score: 0.006
-
Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother. 2007 Dec; 51(12):4297-302.
Score: 0.005